Is intradermal botulinum toxin (Botox) safe for use during pregnancy?

Intradermal Botox in Pregnant Women

Intradermal botulinum toxin should be avoided during pregnancy due to insufficient human safety data and documented fetal toxicity in animal studies at clinically relevant doses.

FDA Drug Label Position

The FDA classifies Botox use in pregnancy with clear warnings based on animal data. There are no adequate studies in pregnant women, and animal studies demonstrate adverse fetal effects including decreased fetal body weight and skeletal ossification at doses comparable to human cosmetic use 1. Specifically:

• Animal studies showed fetal toxicity at doses as low as 4 Units/kg (approximately 4 times the typical human cosmetic dose of 64 Units)
• Higher doses caused maternal toxicity including abortions, early deliveries, and maternal death
• The FDA explicitly states there is no adequate data from postmarketing surveillance on developmental risks in pregnant women 1

Clinical Evidence Analysis

Human Pregnancy Outcomes

The most comprehensive recent systematic review (2026) analyzed 486 pregnancies exposed to botulinum toxin 2:

• 77.7% resulted in healthy infants
• 20.1% resulted in fetal losses (elective, therapeutic, and spontaneous abortions)
• 2.3% had birth defects
• Most exposures occurred in the first trimester
• The authors concluded evidence remains insufficient to establish safety due to significant heterogeneity

Important Caveats

While smaller case series report no adverse outcomes 3, 4, 5, 6, these are limited by:

• Small sample sizes (individual cases or small series)
• Lack of controlled comparison groups
• Potential publication bias (negative outcomes may be underreported)
• The 2026 systematic review explicitly states "no direct association between fetal harm and BoNT-A treatment could be inferred, but evidence remains limited" 2

Practical Clinical Approach

For cosmetic indications: Defer all elective intradermal botulinum toxin injections until after pregnancy and lactation. The risk-benefit ratio does not favor cosmetic use given:

• No medical necessity
• Documented animal teratogenicity at relevant doses
• 20% fetal loss rate in the largest human case series
• Insufficient data to rule out rare or delayed adverse effects

For therapeutic indications (e.g., severe dystonia, chronic migraine affecting quality of life): This requires a different risk-benefit calculation, but intradermal cosmetic use does not fall into this category.

Key Clinical Pitfalls

• Do not rely on the high molecular weight argument alone - while botulinum toxin theoretically should not cross the placenta, animal studies clearly demonstrate fetal effects 1
• First trimester exposure is highest risk - organogenesis occurs during this period when most cosmetic exposures have been reported 2
• Pregnancy testing before cosmetic procedures - verify negative pregnancy test in women of childbearing age before elective botulinum toxin injections

Lactation Considerations

The FDA states there are no data on presence in breast milk or effects on breastfed infants 1. The 2026 survey found 75% of dermatologists reported administering or receiving botulinum toxin while breastfeeding with no reported adverse effects 3, but this represents practice patterns rather than safety evidence.

Bottom line: Intradermal botulinum toxin for cosmetic purposes should be contraindicated in pregnancy given the lack of human safety data, animal teratogenicity at clinically relevant doses, and the elective nature of cosmetic treatments.